Shallow Whole-Genome Sequencing from Plasma Identifies FGFR1 Amplified Breast Cancers and Predicts Overall Survival
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Shallow Whole-Genome Sequencing from Plasma Identifies FGFR1 Amplified Breast Cancers and Predicts Overall Survival
Authors
Keywords
-
Journal
Cancers
Volume 12, Issue 6, Pages 1481
Publisher
MDPI AG
Online
2020-06-09
DOI
10.3390/cancers12061481
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cell-free DNA analysis reveals POLR1D-mediated resistance to bevacizumab in colorectal cancer
- (2020) Qing Zhou et al. Genome Medicine
- Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer
- (2019) Luigi Formisano et al. Nature Communications
- Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups
- (2019) Oscar M. Rueda et al. NATURE
- FGFR1 gene amplification mediates endocrine resistance but retains TORC sensitivity in metastatic hormone receptor positive (HR+) breast cancer
- (2019) Joshua Z Drago et al. CLINICAL CANCER RESEARCH
- Untargeted Assessment of Tumor Fractions in Plasma for Monitoring and Prognostication from Metastatic Breast Cancer Patients Undergoing Systemic Treatment
- (2019) Christoph Suppan et al. Cancers
- Association between FGFR1 copy numbers, MAP3K1 mutations, and survival in axillary node-positive, hormone receptor-positive, and HER2-negative early breast cancer in the PACS04 and METABRIC studies
- (2019) Dimitri Carene et al. BREAST CANCER RESEARCH AND TREATMENT
- Circulating Tumor DNA for Modern Cancer Management
- (2019) Ellen Heitzer CLINICAL CHEMISTRY
- CNV Detection from Circulating Tumor DNA in Late Stage Non-Small Cell Lung Cancer Patients
- (2019) Hao Peng et al. Genes
- Targeting FGFR pathway in breast cancer
- (2018) J. Perez-Garcia et al. BREAST
- Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide
- (2018) Jelena Belic et al. INTERNATIONAL JOURNAL OF CANCER
- Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer
- (2018) Daniel G. Stover et al. JOURNAL OF CLINICAL ONCOLOGY
- The prognostic value of circulating cell-free DNA in breast cancer
- (2018) Guoqiang Tan et al. MEDICINE
- Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma
- (2018) S. Manier et al. Nature Communications
- Single tube liquid biopsy for advanced non‐small cell lung cancer
- (2018) Sanne Wit et al. INTERNATIONAL JOURNAL OF CANCER
- Change in HER2 status after neoadjuvant chemotherapy and the prognostic impact in patients with primary breast cancer
- (2017) Atsushi Yoshida et al. JOURNAL OF SURGICAL ONCOLOGY
- Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors
- (2017) Viktor A. Adalsteinsson et al. Nature Communications
- Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy
- (2017) Daniel H. Hovelson et al. Oncotarget
- Whole-genome plasma sequencing reveals focal amplifications as a driving force in metastatic prostate cancer
- (2016) Peter Ulz et al. Nature Communications
- High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial
- (2016) A. Pearson et al. Cancer Discovery
- rCGH: a comprehensive array-based genomic profile platform for precision medicine
- (2015) Frederic Commo et al. BIOINFORMATICS
- Cross-laboratory validation of the OncoScan® FFPE Assay, a multiplex tool for whole genome tumour profiling
- (2015) Joseph M Foster et al. BMC Medical Genomics
- Massively parallel DNA sequencing from routinely processed cytological smears
- (2015) Laure Piqueret-Stephan et al. CANCER CYTOPATHOLOGY
- Rapid Identification of Plasma DNA Samples with Increased ctDNA Levels by a Modified FAST-SeqS Approach
- (2015) J. Belic et al. CLINICAL CHEMISTRY
- FGFR1 is an adverse outcome indicator for luminal A breast cancers
- (2015) Yu-Jie Shi et al. Oncotarget
- Low Prognostic Implication of Fibroblast Growth Factor Family Activation in Triple-negative Breast Cancer Subsets
- (2014) Hee Jin Lee et al. ANNALS OF SURGICAL ONCOLOGY
- Prognostic Value of FGFR Gene Amplification in Patients with Different Types of Cancer: A Systematic Review and Meta-Analysis
- (2014) Jinjia Chang et al. PLoS One
- Changes in Colorectal Carcinoma Genomes under Anti-EGFR Therapy Identified by Whole-Genome Plasma DNA Sequencing
- (2014) Sumitra Mohan et al. PLoS Genetics
- Noninvasive Detection of HER2 Amplification with Plasma DNA Digital PCR
- (2013) H. Gevensleben et al. CLINICAL CANCER RESEARCH
- Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing
- (2013) Ellen Heitzer et al. Genome Medicine
- Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer
- (2012) Hans-Ulrich Schildhaus et al. MODERN PATHOLOGY
- FAST-SeqS: A Simple and Efficient Method for the Detection of Aneuploidy by Massively Parallel Sequencing
- (2012) Isaac Kinde et al. PLoS One
- FGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer
- (2010) N. Turner et al. CANCER RESEARCH
- Triple-Negative Breast Cancer
- (2010) William D. Foulkes et al. NEW ENGLAND JOURNAL OF MEDICINE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started